What's Happening?
MedImpact Holdings Inc., based in San Diego, has announced the availability of an unbranded biosimilar ustekinumab-aekn at a lower cost compared to the reference drug Stelara®. This biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be accessible for direct purchase by any licensed specialty pharmacy through MedImpact’s preferred partner, Birdi, Inc. The initiative aims to bypass traditional supply chain costs, offering greater value to pharmacies and payers, and providing a more affordable treatment option for patients. The strategy is designed to reduce reliance on rebates and enhance price transparency, allowing payers and members to access lower costs at the point of sale.
AD
Why It's Important?
The introduction of a low-cost biosimilar by MedImpact is significant in the context of rising specialty drug costs and the closure of pharmacies. This strategy provides specialty pharmacies with a new sourcing option and access to lower prices, offering payers across healthcare greater flexibility and control over cost drivers. By using an FDA-designated interchangeable biosimilar, MedImpact aims to increase physician prescribing and patient acceptance, ultimately delivering meaningful cost savings. This move is expected to transform the specialty drug market by expanding access and driving affordability without compromising on quality.
What's Next?
The unbranded ustekinumab-aekn biosimilar is expected to be available for purchase starting January 01, 2026. MedImpact plans to continue expanding its product offerings to further enhance access and affordability in the specialty drug market. Stakeholders, including pharmacies, payers, and patients, are likely to monitor the impact of this strategy on drug pricing and availability closely.
Beyond the Headlines
MedImpact's strategy could lead to broader industry shifts, encouraging other companies to adopt similar approaches to reduce drug costs and improve access. The focus on price transparency and bypassing traditional supply chain costs may set a precedent for future healthcare initiatives aimed at balancing affordability and access.
